eIF4E plays the role of a pathogenic gene in psoriasis, and the inhibition of eIF4E phosphorylation ameliorates psoriasis‐like skin damage

Abstract

AbstractPsoriasis is a complex inflammatory skin disease with uncertain pathogenesis. eIF4E (eukaryotic translation initiation factor 4E) and its phosphorylation state p‐eIF4E are highly expressed in psoriatic tissues. However, the role eIF4E played in psoriasis is still unclear. To investigate the function of eIF4E and p‐eIF4E in psoriasis and to figure out whether eFT‐508 (Tomivosertib, eIF4E phosphorylation inhibitor) can relieve the disease severity and become a promising candidate for the psoriasis treatment. We first verified the expression of eIF4E and p‐eIF4E in psoriasis patients' lesional skin. Then, we demonstrated the effect of eIF4E and p‐eIF4E on the abnormal proliferation and inflammatory state of keratinocytes by using eIF4E‐specific small interfering RNA (si‐eIF4E) and eFT‐508. In this study, all cell experiments were performed under the psoriasis‐model condition. Moreover, the external application of eFT‐508 on imiquimod (IMQ)‐induced psoriasis mice was performed to explore its potential clinical value. Results showed that eIF4E and p‐eIF4E were significantly overexpressed in skin lesions of psoriasis patients. Knocking down eIF4E or adding eFT‐508 can relieve the abnormal proliferation and the excessive inflammatory state of keratinocytes by reducing the expression of cyclin D1, IL‐1β, CXCL10, IL23, Wnt 5a, NBS1 and p‐AKT from mRNA or protein levels. Furthermore, these results were consistent with those obtained from the in vitro experiments. Then, we conclude that eIF4E plays the role of the pathogenic gene in psoriasis, and eFT‐508 may be a promising candidate for anti‐prosoriasis drugs.